reMYND NV, a clinical stage company tackling neurodegeneration, announces that its lead Alzheimer programme ReS19-T has successfully completed its phase 1 study. Topline data has demonstrated excellent brain exposure and strong safety profile. These results support the next phase of clinical development, a Phase 2a proof-of-mechanism study slated for initiation soon.
The phase 1 study investigated RES19-T in 77 healthy volunteers, with doses up to 2
